Ardelyx (NASDAQ: ARDX) draws $50M Term F loan maturing in 2030
Ardelyx, Inc. (NASDAQ: ARDX) has secured a new $50.0 million Term F Loan under its existing loan and security agreement with SLR Investment Corp. and other lenders, with the funding received on June 29, 2026. This loan matures on July 1, 2030, and allows for interest-only payments until maturity, bearing interest at 4.55% plus the greater of the 1-month SOFR reference rate or 3.5%. The funds are intended for general corporate purposes and strategic initiatives, though the agreement includes customary events of default that could accelerate repayment and allow lenders to seize collateral.
Price to book forward of Ardelyx, Inc. – NASDAQ:ARDX
This article provides financial information for Ardelyx, Inc. (NASDAQ: ARDX), specifically focusing on its "Price to book forward" metric. The content appears to be a stub or a section from a financial data platform, highlighting the company's stock information and financial overview without presenting detailed analysis. It also mentions data sources like ICE Data Services and FactSet.
Price to earnings forward of Ardelyx, Inc. – TRADEGATE:41X
This article provides limited financial information for Ardelyx, Inc. (TRADEGATE:41X), focusing on its forward price-to-earnings ratio. The content indicates that market data is closed with no trades, and the report offers a brief overview of financial metrics without specific values. It primarily serves as a placeholder for detailed financial analysis, stating "Made by humans" and attributing data sources.
Ardelyx (ARDX) Faces New Medicare Rules For Xphozah After Court Ruling
A recent U.S. federal appellate court ruling has determined that Ardelyx's drug Xphozah will be included in Medicare's End Stage Renal Disease (ESRD) bundled payment system, rather than being reimbursed separately. This decision concludes a long-standing legal dispute and will alter how dialysis providers are paid for Xphozah, impacting Ardelyx's commercial strategy and potential revenue in dialysis centers. The company, which focuses on kidney disease therapies, now faces adjustments in pricing decisions and product positioning for its key product.
Ardelyx (ARDX) Faces New Medicare Rules For Xphozah After Court Ruling
A U.S. federal appellate court has ruled that Ardelyx's drug Xphozah will be included in Medicare’s End Stage Renal Disease (ESRD) bundled payment system, ending separate reimbursement. This decision impacts how dialysis providers are paid for Xphozah and could influence the drug's pricing and market positioning for Ardelyx. Investors are advised to consider how this ruling affects Medicare revenue potential and adoption patterns, especially alongside recent insider selling.
Ardelyx (ARDX) Faces New Medicare Rules For Xphozah After Court Ruling
A U.S. federal appellate court has ruled that Ardelyx's drug Xphozah will be included in Medicare's ESRD bundled payment system, ending separate reimbursement and potentially impacting the drug's pricing and adoption among dialysis providers. This decision is significant for investors, as it reshapes assumptions about Medicare revenue potential and prompts Ardelyx to adjust its commercial strategy. Despite the ruling, the stock has experienced a recent decline, and investors are advised to consider the implications for fair value and risk factors like insider selling.
Jefferies Maintains Ardelyx(ARDX.US) With Buy Rating, Maintains Target Price $15
Jefferies has reiterated its Buy rating on Ardelyx (ARDX.US) and maintained its target price at $15. This indicates a continued positive outlook from the firm regarding Ardelyx's stock performance.
Ardelyx falls after setback in Xphozah appeal (ARDX:NASDAQ)
Ardelyx shares declined approximately 6% after losing an appeal against the Health and Human Services Department. The appeal concerned a Medicare decision that eliminated Part D coverage for Ardelyx's kidney disease therapy, Xphozah. This setback stems from a lawsuit filed in July regarding the coverage issue.
Ardelyx, Inc. Actuals & Estimates (NASDAQ:ARDX)
Ardelyx, Inc. (NASDAQ:ARDX) stock has seen a decrease of -8.42% in the past 24 hours, with a current price of 5.55 USD, though it has increased by 52.89% over the last year. Analysts provide a future price forecast for ARDX ranging from a maximum estimate of 19.00 USD to a minimum of 13.00 USD. The company is expected to release its next earnings report on July 30, 2026, with recent earnings showing a minor miss and revenues exceeding estimates.
Ardelyx, Inc. Actuals & Estimates (FWB:41X)
This article provides financial actuals and estimates for Ardelyx, Inc. (FWB:41X), covering its income statement, balance sheet, and cash flow. It includes analyst forecasts, historical price data, earnings reports, revenue, net income, and information about the company's employees and EBITDA, noting that the company does not pay dividends.
Is Ladenburg’s IBSRELA Focus Quietly Reframing Ardelyx’s (ARDX) Risk‑Reward Story?
Investment bank Ladenburg initiated coverage on Ardelyx (ARDX), highlighting the growing demand for IBSRELA and continued commercial success of XPHOZAH, aligning with management's ambitious long-term revenue projections. This new coverage reinforces IBSRELA's central role as a key growth driver for Ardelyx, despite existing market risks. The article examines how this focus could influence the company's investment narrative and risk-reward profile, particularly in light of an insider stock sale and varying analyst forecasts for its future revenue and earnings.
Is Ladenburg’s IBSRELA Focus Quietly Reframing Ardelyx’s (ARDX) Risk‑Reward Story?
Investment bank Ladenburg recently initiated coverage on Ardelyx (ARDX), highlighting the growing demand for IBSRELA and continued commercial success of XPHOZAH, alongside management's ambitious long-term revenue targets. This new coverage reinforces IBSRELA's role as a key growth catalyst, with the company aiming for at least $1.0 billion in annual IBSRELA revenue by 2029. While a recent insider stock sale occurred under a pre-set plan, Ardelyx's reliance on these two tenapanor products emphasizes the importance of prescription growth and market access for future profitability.
Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last?
Aquestive Therapeutics (AQST) saw its shares rally 6.6% after a session of notable trading volume, reflecting growing investor confidence. The company awaits the resubmission of its new drug application for Anaphylm, a needle-free epinephrine sublingual film, in Q3 2026, and is also advancing other pipeline candidates. Despite positive commercial prospects, the consensus EPS estimate for the upcoming quarter has remained unchanged, leading Zacks to issue a "Hold" rating for the stock.
Ardelyx Inc (ARDX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Ardelyx Inc (ARDX), detailing its current price momentum score, support and resistance levels, and indicator and moving average signals. It notes ARDX has a price momentum score of 8.91 and is trading between a resistance of $6.66 and a support of $5.50. The analysis concludes with a "Buy" signal based on moving averages and a mix of buy, sell, and neutral signals from various technical indicators.
Ardelyx Stock Up 70%: What to Know About This $490,000 Insider Transaction
Ardelyx Chief Patient Officer Laura Williams sold 81,898 shares of Common Stock for approximately $490,000, reducing her direct holdings by 17.8% after the stock rallied 70% over the past year. The transaction, executed under a 10b5-1 trading plan, involved the exercise of stock options. Despite the sale, Williams retains substantial ownership, and Ardelyx continues to show strong operational execution with significant revenue growth and positive guidance for future product sales.
Form 4 Ardelyx Inc For: 22 June By Investing.com
This article from Investing.com is a brief announcement regarding a Form 4 filing for Ardelyx Inc., dated June 22. It provides no further details beyond the filing's existence and is accompanied by various financial market data and unrelated news headlines.
Ardelyx chief patient officer sells $490k in stock By Investing.com
Laura A. Williams, Chief Patient Officer at Ardelyx, Inc. (NASDAQ: ARDX), sold 81,898 shares of company stock for approximately $490,487 and exercised options for 31,000 shares valued at $30,690, all under a pre-arranged 10b5-1 trading plan. The transactions occurred on June 18, 2026, with sales at prices ranging from $5.97 to $6.0086 and options exercised at $0.99 per share. InvestingPro analysis suggests Ardelyx is undervalued, despite recent Q1 2026 earnings reporting a net loss that missed expectations.
Ardelyx (ARDX) Chief Patient Officer sells shares, exercises 31,000 options
Ardelyx, Inc.'s Chief Patient Officer, Laura A. Williams, sold 81,898 shares of common stock at a weighted average price of $5.989 per share. This sale was conducted under a Rule 10b5-1 trading plan adopted on March 19, 2026. Concurrently, Williams exercised stock options to acquire 31,000 shares at an exercise price of $0.99 per share, and she now directly holds 378,195 shares of Ardelyx common stock.
Form 4 Ardelyx Inc For: 22 June By Investing.com
This article reports on a Form 4 filing for Ardelyx Inc. on June 22. It briefly mentions the stock symbol ARDX and its performance for the day. The core content is very minimal, essentially just stating the filing occurred, with the remainder of the page comprising market data, news links, and site navigation.
Ardelyx chief patient officer sells $490k in stock
Ardelyx Inc.'s Chief Patient Officer, Laura A. Williams, sold approximately $490,487 worth of company stock while simultaneously exercising stock options valued at $30,690. These transactions occurred on June 18, 2026, under a pre-arranged 10b5-1 trading plan. The article also notes that Ardelyx appears undervalued according to InvestingPro analysis, despite recent quarterly earnings missing expectations but showing strong year-over-year growth.
Ardelyx (ARDX) director receives RSUs and stock options as compensation
Ardelyx, Inc. director Muna Bhanji received 26,455 restricted stock units (RSUs) and options for 39,715 shares with an exercise price of $5.6700 per share, expiring on June 16, 2036. These equity grants were part of the company's Non-Employee Director Compensation Program. Following these transactions, Bhanji directly holds 163,808 shares of Ardelyx common stock.
Ardelyx (ARDX) director receives 26,455 RSUs and 39,715-share option
Ardelyx director Richard J. Rodgers received new equity awards as part of the company's Non-Employee Director Compensation Program. He was granted 26,455 restricted stock units (RSUs) and a stock option for 39,715 shares with an exercise price of $5.67 per share. These awards increase his direct holdings to 439,998 common shares, with vesting details provided for both the RSUs and the stock option.
Ardelyx Inc (ARDX) Earnings Forecast: Future EPS & Revenue Growth Estimates
Ardelyx Inc (ARDX) has an earnings forecast score of 9.27, placing it highly within the Biotechnology & Medical Research industry. Analysts have a strong buy rating for ARDX, with an average price target of $11.00 and expectations for positive revenue growth. The company's EPS for the previous quarter exceeded market expectations and is projected to be negative but improved for the next quarter.
Ardelyx Inc (ARDX) Institutional Confidence
Ardelyx Inc (ARDX) currently holds an institutional shareholding score of 7.00, placing it 81st in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 71.25%, showing a 7.13% decrease quarter-over-quarter. Steven Cohen is the largest institutional shareholder with 2.90 million shares, representing 1.21% of outstanding shares.
Equity grants to Ardelyx (ARDX) director under compensation program
Ardelyx director David M. Mott received equity awards through the company’s Non-Employee Director Compensation Program. These awards included 46,737 shares of common stock at no cash cost and a stock option for 39,715 shares with an exercise price of $5.67, expiring in 2036. The shares and options vest over time, with some shares held for entities associated with New Enterprise Associates.
Ardelyx (ARDX) director granted RSUs and 39,715-share stock option
Ardelyx director Merdad Parsey was granted 26,455 restricted stock units (RSUs) and a stock option for 39,715 shares at an exercise price of $5.67, under the company's Non-Employee Director Compensation Program. These awards are equity compensation, not open-market trades. Following these grants, Parsey directly holds 83,746 shares of Ardelyx common stock.
Ardelyx (ARDX) director Cadoret-Manier receives RSU and option grants
Ardelyx (ARDX) director Onaiza Cadoret-Manier was granted 26,455 restricted stock units (RSUs) and stock options for 39,715 shares on June 16, 2026, as part of the company's Non-Employee Director Compensation Program. Following these grants, her direct holdings in common stock total 178,156 shares. The stock options have an exercise price of $5.67 per share, an expiration date of June 16, 2036, and vest monthly with accelerated vesting at the next annual stockholders' meeting.
Ardelyx (ARDX) director Robert Bazemore receives RSU and option awards
Ardelyx (ARDX) director Robert Bazemore was granted 26,455 restricted stock units (RSUs) and stock options for 39,715 shares as equity compensation under the company's Non-Employee Director Compensation Program. The RSUs will convert to common stock upon vesting, bringing his direct holdings to 68,006 shares. The stock options have an exercise price of $5.67 per share, vest over 12 months, and expire on June 16, 2036.
Ardelyx (ARDX) Stock Could Be 65% Undervalued As Growth Hopes Face Reassessment
Ardelyx (ARDX) stock, currently trading at $5.67, is seen as potentially 65% undervalued by analysts, with a fair value target near $16.33. This optimistic outlook is based on projected revenue growth from its core products, IBSRELA and XPHOZAH, benefiting from increasing chronic kidney disease prevalence and improved market access. However, investors are advised to consider risks such as heavy reliance on these two products and uncertainty surrounding XPHOZAH's Medicare reimbursement.
Ardelyx shareholders approve director elections and equity plan amendment
Ardelyx shareholders approved the election of three Class III directors, a non-binding advisory vote on executive compensation, and the appointment of Ernst & Young LLP as their independent registered public accounting firm. They also approved an amendment to the company's 2014 Equity Incentive Award Plan. The company's shares are currently trading at $5.84, with a 64.5% return over the past year, and analysts give it a "Strong Buy" consensus.
Ardelyx Inc (ARDX) Financial Health: Profitability & Balance Sheet Analysis
Ardelyx Inc (ARDX) has a current financial score of 7.76, placing it 86th out of 388 in the Biotechnology & Medical Research industry, indicating a weak financial status but high operating efficiency. The company recently reported a 27.47% year-over-year increase in quarterly revenue, reaching $94.47 million, and an 8.60% year-over-year increase in net profit. However, several specific financial data points like cash and cash equivalents, total assets, and free cash flow have not been disclosed by the company.
Ardelyx shareholders approve director elections and equity plan amendment
Ardelyx, Inc. (NASDAQ:ARDX) shareholders approved the election of three Class III directors and an amendment to the company's 2014 Equity Incentive Award Plan at its 2026 Annual Meeting. They also passed a non-binding advisory vote on executive compensation and ratified Ernst & Young LLP as the independent registered public accounting firm. The company's stock has seen a 64.5% return over the past year and is considered undervalued by InvestingPro analysis despite recent Q1 2026 financial results missing some forecasts.
Ardelyx Inc (ARDX) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Ardelyx Inc (ARDX), identifying its major institutional holders including Millennium Management LLC, BlackRock, and Janus Henderson Investors. It provides a breakdown of shareholder types, institutional shareholding over time from Q1 2024 to Q1 2026, and recent changes in holdings by key investors. Additionally, the article lists various ETFs with holdings in Ardelyx Inc.
Ardelyx Inc (ARDX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Ardelyx Inc (ARDX), detailing its performance by business segment and geographical region. For the period updated on April 6, the company's revenue primarily comes from its IBSRELA and XPHOZAH products, with IBSRELA contributing a significant 72.58%. All reported revenue originates from the United States, accounting for 100% of its regional revenue.
Ardelyx approves Equity Plan Amendment at 2026 Annual Meeting
Ardelyx's stockholders approved the Second Amendment to the Amended and Restated 2014 Equity Incentive Award Plan at the company's 2026 Annual Meeting. This amendment was made effective on June 16, 2026, following stockholder approval. Further details are available in the Proxy Statement filed on April 29, 2026, and the full text as Exhibit 10.1 of their SEC filing.
Ardelyx (NASDAQ: ARDX) shareholders approve equity plan, directors and auditor at 2026 meeting
Ardelyx, Inc. shareholders approved all five proposals at their 2026 Annual Meeting. Key approvals include the election of three Class III directors, the ratification of Ernst & Young LLP as the independent auditor, and the Second Amendment to the Amended and Restated 2014 Equity Incentive Award Plan. Shareholders also supported an annual Say-On-Pay vote, indicating confidence in the company's governance and compensation practices.
ARDX insider Michael G. Raab sells 179,748 shares (NASDAQ: ARDX)
Michael G. Raab, an insider at Ardelyx (NASDAQ: ARDX), reported the sale of 179,748 shares of common stock through multiple dispositions between March and May 2026. The sales, detailed in a Form 144/A filing, generated proceeds totaling over $1 million and originated from stock option exercises, restricted stock units (RSUs), and an employee stock purchase plan. The filing serves as a compliance notice rather than an indication of future trading plans.
Ardelyx (ARDX) CEO trades shares under 10b5-1 plan, exercises options
Ardelyx (ARDX) President & CEO Michael Raab engaged in mixed equity activity on June 15, 2026, selling 41,666 common shares at a weighted average price of $5.6724 under a Rule 10b5-1 trading plan adopted in November 2025. Simultaneously, he exercised stock options to acquire 20,833 common shares at an exercise price of $0.99 per share. Following these transactions, Raab directly holds 1,699,200 common shares and retains 311,668 outstanding stock options, along with indirect holdings through family trusts.
Ardelyx (ARDX) Stock Could Be 65% Undervalued As Growth Hopes Face Reassessment
Ardelyx (ARDX) stock is currently trading at $5.67, significantly below the average analyst price target of $16.33, indicating a potential undervaluation of 65%. This valuation is based on assumptions of strong revenue growth driven by expanding markets for IBSRELA and XPHOZAH and improved market access. However, investors are urged to consider risks such as product reliance and reimbursement uncertainty.
Assessing Ardelyx (ARDX) Valuation After Recent Share Price Pullback And Growth Expectations
Ardelyx (ARDX) has experienced a significant short-term share price pullback, down 24% over the past month, despite a 48.4% one-year return. Analysts view the stock as undervalued, with a fair value target of US$16.33 compared to its current US$5.40, driven by expanding markets for its products IBSRELA and XPHOZAH and an anticipated sharp profit swing. Investors are encouraged to review the full narrative, including potential risks like Medicare reimbursement and ongoing legal proceedings, before making investment decisions.
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx
Faruqi & Faruqi, LLP is investigating potential securities fraud claims against Ardelyx, Inc. (NASDAQ: ARDX) and reminds investors of the October 15, 2024 deadline to seek lead plaintiff status in a federal securities class action. The lawsuit alleges that Ardelyx made misleading statements regarding its intent to include its drug XPHOZAH in TDAPA, which negatively impacted the stock price when the company later decided against it. Investors who suffered losses exceeding $100,000 between October 31, 2023, and July 1, 2024, are encouraged to contact the firm.
Assessing Ardelyx (ARDX) Valuation After Recent Share Price Pullback And Growth Expectations
Ardelyx (ARDX) has experienced a significant share price pullback, down 24% over the past month, leading investors to re-evaluate its valuation. Despite the short-term pressure, the stock is considered 66.9% undervalued with a fair value of US$16.33, primarily driven by expectations of rapid top-line expansion and growth in its core addressable markets due to an aging population and improved market access for its products, IBSRELA and XPHOZAH. Investors are encouraged to review the company's prospects and risks, including reliance on its key products and exposure to Medicare reimbursement.
ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%?
Ardelyx Inc. (ARDX) shares experienced a pre-market decline of nearly 8% after its Q4 earnings failed to meet Wall Street expectations. Despite this, H.C. Wainwright analysts significantly increased their price target for ARDX by 80%, from $10 to $18, while maintaining a 'Buy' rating. This positive outlook is primarily due to Ardelyx securing a new patent for oral formulations of Tenapor, including Ibsrela and Xpozah, which extends protection until November 2042 and has been listed in the FDA's Orange Book.
Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach
Ardelyx (ARDX) expects over $500 million in revenue this year, primarily driven by its IBS-C treatment IBSRELA, which is projected to bring in $410 million to $430 million. The company is actively expanding market reach for IBSRELA and XPHOZAH, while advancing its pipeline and aiming for sustainable profitability. Ardelyx is also conducting a Phase 3 trial for IBSRELA in chronic idiopathic constipation, a market significantly larger than IBS-C, as it eyes long-term revenue goals and profitability, possibly as early as this year.
Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach
Ardelyx projects over $500 million in revenue for 2026, driven primarily by IBSRELA, its irritable bowel syndrome treatment, which is expected to bring in $410 million to $430 million. The company aims for $1 billion in IBSRELA revenue by 2029 and sees potential for profitability this year, although it is holding off on formal guidance until sustainability is confirmed. Growth strategies include an expanded sales force, enhanced prescription fulfillment via a specialty pharmacy network, and direct physician outreach.
ARDX Edges Up After Hours On IBSRELA Momentum And Profitability ‘Right Around The Corner’
Ardelyx Inc. (ARDX) shares rose in after-hours trading following renewed guidance for its drug IBSRELA and expectations of profitability soon. The company anticipates combined revenue from IBSRELA and XPHOZAH to exceed $500 million this year, with a long-term target of $1 billion for IBSRELA by 2029. Ardelyx also outlined strategic priorities for 2026, including sales force expansion and advancing its pipeline, while retail sentiment remains bullish with analysts rating the stock a "Buy."
ARDX: IBSRELA and XPHOZAH are set for robust growth, targeting $1B and $750M revenues by 2029
Ardelyx, Inc. (ARDX) projects strong revenue growth for its drugs IBSRELA and XPHOZAH, with 2026 revenue expected to exceed $500 million. The company aims for long-term targets of $1 billion for IBSRELA and $750 million for XPHOZAH by 2029, supported by strategic investments in sales, marketing, R&D, and new patent protection, signaling confidence in sustained growth and near-term profitability. This outlook is based on insights from the Jefferies Global Healthcare Conference 2026.
IBSRELA-Fueled Q1 Surge and AI Spotlight Could Be A Game Changer For Ardelyx (ARDX)
Ardelyx (ARDX) experienced a significant 58% year-over-year revenue growth in Q1 2026, primarily driven by its IBS-C therapy, IBSRELA. This growth, coupled with increased attention from AI-driven stock rankings, highlights the drug's strong commercial momentum. However, the company still faces challenges including a narrow product base, ongoing losses, and reimbursement uncertainties for its other key product, XPHOZAH, despite reiterating revenue guidance for 2026.
IBSRELA-Fueled Q1 Surge and AI Spotlight Could Be A Game Changer For Ardelyx (ARDX)
Ardelyx reported a 58% year-over-year revenue growth in Q1 2026, primarily driven by its IBS-C therapy, IBSRELA, which has caught the attention of AI-driven stock rankings. The company's investment narrative focuses on the potential of IBSRELA and XPHOZAH to achieve profitability despite a narrow product base and reimbursement uncertainty, projecting significant revenue and earnings growth by 2029. This growth is anticipated to lead to a substantial upside in Ardelyx's stock value, according to fair value estimates.
ARDX Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Ardelyx Inc (ARDX), indicating a "Strong Sell" consensus based on various technical indicators and moving averages. Key metrics like MACD and moving averages suggest bearish momentum, with the stock trading below its significant long-term moving averages. The analysis also outlines crucial support and resistance levels for potential future price movements.
